Insulet (NASDAQ:PODD) Issues Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Insulet (NASDAQ:PODD) posted its quarterly earnings data on Wednesday. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23, FiscalAI reports. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same period in the prior year, the company earned $1.02 EPS. The firm’s revenue was up 33.9% compared to the same quarter last year. Insulet updated its FY 2026 guidance to 6.210- EPS.

Here are the key takeaways from Insulet’s conference call:

• Insulet delivered a strong Q1 with 30% constant-currency revenue growth ($762M, +34% reported), expanded adjusted operating margin +110bps, ~40% adjusted EPS growth, raised full‑year revenue guidance to 21–23%, and completed a $300M share repurchase while ending the quarter with $480M cash and full $500M credit availability.
• International momentum remains a key growth driver — 45% constant‑currency revenue growth, third consecutive quarter above 40%, broader reimbursement (now 85% of Canada) and planned market/ sensor launches including Spain and FreeStyle Libre 3 Plus in Germany and Canada.
• The product roadmap was emphasized as a catalyst — algorithm enhancements (new 100 mg target estimated to improve time‑in‑range ~5%), FreeStyle Libre 3 Plus integration, Omnipod 6 with a next‑gen algorithm in 2027, and an enrolled pivotal EVOLVE study toward a fully closed‑loop type‑2 system targeting FDA submission and a 2028 launch.
• Operational and regulatory risk from a voluntary Medical Device Correction (≈$12M GAAP charge; >150bps adjusted gross‑margin impact from E&O) and an FDA communication about misreported MDRs introduces reputational and regulatory uncertainty, although management says targeted fixes are implemented and no new adverse events have been reported.

Insulet Trading Down 9.7%

Shares of NASDAQ:PODD traded down $16.25 during midday trading on Wednesday, reaching $151.28. 4,460,444 shares of the company’s stock were exchanged, compared to its average volume of 1,123,353. The firm’s 50 day simple moving average is $212.92 and its two-hundred day simple moving average is $264.96. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. The stock has a market cap of $10.48 billion, a price-to-earnings ratio of 43.22, a P/E/G ratio of 0.99 and a beta of 1.20. Insulet has a fifty-two week low of $148.30 and a fifty-two week high of $354.88.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 beat and stronger-than-expected revenue: Insulet reported $1.42 EPS and $761.7M revenue (up ~34% YoY), topping estimates and exceeding the high end of its guidance range; management raised the annual revenue-growth outlook on strong Omnipod demand. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Product pipeline progress: Insulet initiated the EVOLVE pivotal study to advance a fully closed‑loop automated insulin delivery system, supporting longer‑term growth potential for higher‑value products. Insulet Initiates EVOLVE Pivotal Study
• Positive Sentiment: Analyst sentiment and technical setup: Some analysts and screens note the stock is technically oversold after recent declines, which could attract buyers if fundamentals remain strong. Insulet (PODD) Loses 17.3% in 4 Weeks
• Neutral Sentiment: Earnings call & transcripts available for detail: Management commentary and the slide deck give more color on margin cadence and the cadence of Omnipod shipments — important for assessing whether the beat is sustainable. Insulet (PODD) Q1 2026 Earnings Transcript
• Negative Sentiment: Guidance nuance: FY 2026 EPS guidance was provided slightly below some consensus figures (management set EPS guidance around 6.21 vs. some street estimates ~6.33), which tempers the upside from the quarter. Insulet Q1 Results & Guidance (MarketBeat)
• Negative Sentiment: Analyst price-target cut: BTIG lowered its price target from $320 to $260 (still a buy), which may signal more conservative near‑term expectations and contributed to selling pressure. BTIG Lowers Price Target (Benzinga)

Analyst Upgrades and Downgrades

PODD has been the subject of several recent research reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $325.00 price objective on shares of Insulet in a research note on Tuesday, April 14th. Raymond James Financial cut their target price on Insulet from $385.00 to $355.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. BTIG Research cut their target price on Insulet from $320.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday. Leerink Partners cut their target price on Insulet from $386.00 to $360.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. Finally, Stifel Nicolaus cut their target price on Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Eighteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average price target of $324.38.

Insider Activity

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.36% of the company’s stock.

Institutional Trading of Insulet

Hedge funds and other institutional investors have recently modified their holdings of the business. Meeder Advisory Services Inc. increased its position in shares of Insulet by 6.4% during the 4th quarter. Meeder Advisory Services Inc. now owns 878 shares of the medical instruments supplier’s stock worth $250,000 after purchasing an additional 53 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Insulet by 46.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 736 shares of the medical instruments supplier’s stock valued at $209,000 after acquiring an additional 235 shares during the period. Quarry LP boosted its holdings in Insulet by 896.4% during the 3rd quarter. Quarry LP now owns 548 shares of the medical instruments supplier’s stock valued at $169,000 after acquiring an additional 493 shares during the period. Advisory Services Network LLC purchased a new position in Insulet during the 3rd quarter valued at about $118,000. Finally, GW&K Investment Management LLC boosted its holdings in Insulet by 40.1% during the 4th quarter. GW&K Investment Management LLC now owns 346 shares of the medical instruments supplier’s stock valued at $98,000 after acquiring an additional 99 shares during the period.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.